Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 721744-CS3 Open-Label Extension in Hereditary Angioedema
2024-517249-15-00Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2024
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of donidalorsen in hereditary angioedema (HAE), sponsored by Ionis Pharmaceuticals. Primary endpoint: Percentage of participants with at least one treatment-emergent adverse event (TEAE), graded by severity. Started Nov 2024; status: completed.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2024-517249-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517249-15-00.